EPARs - Atriance//nelarabine

FICHA FARMACOLÓGICA de nelarabine. Contiene la Monografía en distintos idiomas (de la Comunidad Económica Europea), así como la discusión científica que sustenta su aprobación terapéutica. Para acceder a la monografía en idioma español, hacer doble clik en la sigla (es) en la fila que se sitúa más abajo del centro de la página oficial. Cerasale. ABRIL 19, 2009.-

abrir aquí:
EPARs for authorised medicinal products for human use - Atriance

Active Substance
nelarabine
International Nonproprietary Name or Common Name
nelarabine
Pharmaco-therapeutic Group
Purine analogues
ATC Code
L01BB07

Therapeutic Indication:
Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.

Due to the small patient populations in these disease settings, the information to support these indications is based on limited data.

Date of issue of Marketing Authorisation valid throughout the European Union
22 August 2007

Orphan medicinal product designation date
16 June 2005

EPARs for authorised medicinal products for human use